Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.36 |
| ▸ | S100B | P04271 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017452 | 0.88 | NOTUM (0.47) | NOTUMCSF1RALDH1A1PRMT6GAA | |
| SCHEMBL250634 | 0.88 | NOTUM (0.47) | NOTUMCSF1RALDH1A1PRMT6GAA | |
| SCHEMBL4556485 | 0.83 | NOTUM (0.46) | NOTUMALDH1A1PRMT6KDM4EFFAR4 | |
| SCHEMBL22350762 | 0.83 | NOTUM (0.48) | NOTUMPOLBLMNAMAPT | |
| SCHEMBL13736051 | 0.77 | ALDH1A1 (0.42) | CSF1RALDH1A1PRMT6KDM4EGAA | |
| SCHEMBL25201540 | 0.76 | S1PR1 (0.42) | NOTUM | |
| SCHEMBL4023577 | 0.76 | ALDH1A1 (0.50) | CSF1RALDH1A1PRMT6GAAHTT | |
| SCHEMBL4029065 | 0.76 | ALDH1A1 (0.50) | CSF1RALDH1A1PRMT6GAAHTT | |
| SCHEMBL16729408 | 0.76 | NOTUM (0.50) | NOTUMALDH1A1GAAMEN1MAPT | |
| SCHEMBL4027973 | 0.76 | ALDH1A1 (0.50) | CSF1RALDH1A1PRMT6GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| EP-1572632-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | XENTION LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1572632-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | XENTION LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20060135505-A1 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | BAYER HEALTHCARE AG (DE) | 2006-06-22 | — | — | US | disclosed |
| EP-1572632-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052845-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135505-A1 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | OPRL1, PTGER1, LTB4R2 | NOTUM 2667/4885CSF1R 1943/4885ALDH1A1 405/4885 |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | OPRL1, TRPV1, LTB4R | NOTUM 2396/4885CSF1R 1972/4885ALDH1A1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.